Letter

Local research ethics committees should review their approval of prevention trial

BMJ 1996; 312 doi: 10.1136/bmj.312.7037.1036a (Published 20 April 1996)
Cite this as: BMJ 1996;312:1036.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Catherine Read
  1. Science writer 33 Cockshutt Road, Beauchief, Sheffield S8 7DY

    EDITOR,—R D Bulbrook's editorial discusses who should take tamoxifen and for how long.1 The British aTTom (adjuvant tamoxifen treatment offer more) trial aims to recruit up to 20000 women with primary breast cancer. Many of these women could receive at least seven years' treatment with tamoxifen—two years more than the National Cancer Institute considers routinely advisable for …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular